Dr. Nadia Akhmed, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3168 Braverton St, 330, Edgewater, MD 21037 Phone: 410-956-3090 Fax: 410-956-3063 |
Dr. Ellen Rose Mcinerney, M. D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 137 Mitchells Chance Rd, Suite 180, Edgewater, MD 21037 Phone: 410-224-8220 |
Eric Charles Marcalus, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3168 Braverton St, Suite 250, Edgewater, MD 21037 Phone: 410-956-1600 Fax: 410-956-7900 |
Mr. Johannes Blom, MD Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 4136 Cadle Creek Rd, Edgewater, MD 21037 Phone: 410-798-1127 Fax: 410-798-1127 |
Dr. James Andrew Clyne, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 137 Mitchells Chance Rd Ste 180, Edgewater, MD 21037 Phone: 410-224-8220 |
News Archive
Medical device manufacturer Guidant LLC, a wholly-owned subsidiary of Boston Scientific Corporation, was charged today with criminal violations of the Federal Food, Drug, and Cosmetic Act related to safety problems with some of its implantable defibrillators. Guidant LLC formerly did business as Guidant Corporation. The Justice Department filed the criminal information today in connection with an agreement with Guidant to resolve the charges. A formal guilty plea agreement is expected to be filed with the court at a later date.
The Oregon state legislature cleared two reform bills that passed its House of Representatives earlier this week, the Portland Oregonian reports.
The American College of Occupational and Environmental Medicine (ACOEM) has joined the American Heart Association, the American Lung Association, and other leading organizations to formally oppose S.J. Res. 37, a resolution by Senator James Inhofe (R-Okla) that employs the Congressional Review Act to reverse the U.S. Environmental Protection Agency's (EPA) Mercury and Air Toxics Standards for Power Plants.
There's a high rate of depression among patients with hepatitis C, but a standard treatment for the disease includes a drug, interferon, that can cause depression.
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.
› Verified 6 days ago